High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Rim Halaby moved page High density lipoprotein landmark trials to High density lipoprotein complete list of trials |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{High density lipoprotein}} | |||
{{CMG}}; {{AE}} {{AN}}; {{RT}} | |||
==Reconstituted HDL Infusion== | |||
{| style="font-size:120%" | |||
|- | |||
| [[CHI-SQUARE Study]] | |||
|- | |||
| [[CSL-112 Trial - Phase 1]] | |||
|- | |||
| [[CSL-112 Trial - Phase 2a]] | |||
|- | |||
| [[ERASE Trial]] | |||
|- | |||
| [[Infusion of Apo A-1 Milano]] | |||
|- | |||
|} | |||
==CETP Inhibitors== | |||
{| style="font-size:120%" | |||
|- | |||
| [[ACCELERATE Trial]] | |||
|- | |||
| [[DAL-Outcomes Trial]] | |||
|- | |||
| [[DEFINE Trial]] | |||
|- | |||
| [[ILLUMINATE Trial]] | |||
|- | |||
| [[ILLUSTRATE Trial]] | |||
|- | |||
| [[REVEAL Trial]] | |||
|- | |||
|} | |||
==Niacin== | |||
{| style="font-size:120%" | |||
|- | |||
| [[AIM-HIGH Trial]] | |||
|- | |||
| [[ARBITER 2 Trial]] | |||
|- | |||
| [[ARBITER 3 Trial]] | |||
|- | |||
| [[ARBITER 6-HALTS Trial]] | |||
|- | |||
| [[CLAS Trial]] | |||
|- | |||
| [[HATS Trial]] | |||
|- | |||
| [[Oxford Niaspan Study]] | |||
|- | |||
|} | |||
==Fibrate== | |||
{| style="font-size:120%" | |||
|- | |||
| [[VA-HIT Trial]] | |||
|- | |||
| [[BECAIT Trial]] | |||
|- | |||
| [[BIP Trial]] | |||
|- | |||
|} | |||
==Statin== | |||
{| style="font-size:120%" | |||
|- | |||
| [[ASTEROID Trial]] | |||
|- | |||
| [[SATURN Trial]] | |||
|- | |||
| [[4S Trial]] | |||
|- | |||
| [[CORONA Trial]] | |||
|- | |||
|} | |||
==Multiple Lipid Lowering Drugs== | |||
{| style="font-size:120%" | |||
|- | |||
| [[HARP Study]] | |||
|- | |||
| [[AFREGS Trial]] | |||
|- | |||
|} | |||
{{Lipopedia}} | |||
[[Category:Lipopedia]] | |||
[[Category:Lipid disorders]] | |||
[[Category:Cardiology]] | |||
[[Category:Lipoproteins]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 14:54, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein landmark trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
|
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Reconstituted HDL Infusion
| CHI-SQUARE Study |
| CSL-112 Trial - Phase 1 |
| CSL-112 Trial - Phase 2a |
| ERASE Trial |
| Infusion of Apo A-1 Milano |
CETP Inhibitors
| ACCELERATE Trial |
| DAL-Outcomes Trial |
| DEFINE Trial |
| ILLUMINATE Trial |
| ILLUSTRATE Trial |
| REVEAL Trial |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |